AXSM FY 2024 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$386M+42.5% YoY

Gross Profit

$352M91.4% margin

Operating Income

-$281M-72.7% margin

Net Income

-$287M-74.5% margin

EPS (Diluted)

$-5.99

Cash Flow

Operating Cash Flow

-$128M

Free Cash Flow

-$129M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$568M

Total Liabilities

$511M

Stockholders' Equity

$57M

Cash & Equivalents

$315M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$386M	$271M	+42.5%
Gross Profit	$352M	$245M	+44.1%
Operating Income	-$281M	-$232M	-21.0%
Net Income	-$287M	-$239M	-20.1%